Anti-vascular endothelial growth factor for diabetic macular oedema
about
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathyBlood pressure control for diabetic retinopathyInterventions to increase attendance for diabetic retinopathy screeningAnti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedemaRole of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implantThe clinical utility of aflibercept for diabetic macular edemaAnti-VEGF Therapy and the Retina: An UpdatePerspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedemaThe role of aflibercept in the management of diabetic macular edemaSystematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME)Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?The empirical evidence for the telemedicine intervention in diabetes management.Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal ImplantAflibercept, bevacizumab, or ranibizumab for diabetic macular edemaWnting out ocular neovascularization: using nanoparticle delivery of very-low density lipoprotein receptor extracellular domain as Wnt pathway inhibitor in the retina.Effects of focal/grid laser treatment on the central visual field in diabetic macular oedema: a 2-year follow-up study.Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular EdemaCombination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.Case Series Investigating the Efficacy and Safety of Bilateral Fluocinolone Acetonide (ILUVIEN(®)) in Patients with Diabetic Macular Edema: 10 Eyes with 12 Months Follow-up.Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction.Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.The Prevention and Treatment of Retinal Complications in Diabetes.β2-Adrenergic Receptor Antagonism Attenuates CNV Through Inhibition of VEGF and IL-6 Expression.Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.The regulatory role of hepatoma-derived growth factor as an angiogenic factor in the eye.Situational analysis of services for diabetes and diabetic retinopathy and evaluation of programs for the detection and treatment of diabetic retinopathy in India: Methods for the India 11-city 9-state studyMetabolomic profiling of reactive persulfides and polysulfides in the aqueous and vitreous humors.Long-term Comparative Effectiveness of Telemedicine in Providing Diabetic Retinopathy Screening Examinations: A Randomized Clinical Trial.Molecular mechanisms of diabetic retinopathy: potential therapeutic targets.Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases.Tuberculosis-diabetes co-morbidity is characterized by heightened systemic levels of circulating angiogenic factors.Evaluating the impact of optical coherence tomography in diabetic retinopathy screening for an Aboriginal population.Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society).Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathyLicence to save: a UK survey of anti-VEGF use for the eye in 2015.Predictors of uptake of eye examination in people living with diabetes mellitus in three counties of Kenya.Interventions to increase attendance for diabetic retinopathy screening.EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo.Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.
P2860
Q24186424-DF2BB908-77EB-42D1-AF86-C68F370E87E9Q24186434-C274D991-1BA0-4C2C-9310-5C82DD01EA3CQ24186687-BC56347D-B2A2-48F2-B1F8-5745DA672390Q24187587-8E6B98E6-1F64-461F-9694-0E2FED717CE7Q26775853-80BB270A-2343-4BEE-B1A7-08FA23CB2D10Q26783575-7AE5B9D4-1007-4DED-9913-A7B088EE1737Q26784605-7E8661CF-AD25-4CED-BBC3-D7FDE0CC1AAFQ26786012-E0B15365-0AFF-4DE1-851B-B25E09ED3F08Q26798348-5335B2F7-D011-4C13-82FD-CDCA6EE2677CQ26823985-43C2AA05-0AB1-4A6C-A4F7-EC368D0130ACQ28066675-E8D04E40-8FA4-4B15-A7AE-41A2666C3E20Q30384846-AAFBEFDB-5184-408D-A915-554311F6BD95Q34558187-40514576-A333-45A2-8435-6D9FD090202AQ35559508-3553AB54-F5F8-44E0-98A0-65D7750C04F2Q35575496-8A238F7B-BFFE-4675-AA9D-6097A46E4D52Q35597138-4AAE8749-8886-4D98-92D1-F9DAAFF6AA99Q35902876-AA1D1CD5-1640-43CA-98C9-DCCC080BF481Q35925938-FA265F9E-C388-4C7D-8ED3-D15C3994F616Q35984696-2914D240-3775-456B-880F-17FEA4BC48F0Q35999681-DF74F595-8597-471B-A374-4F9E66F9FC42Q36157251-BCC7975C-7A2F-449A-9714-4DA198280428Q36224527-1E09620A-9657-4AC7-AA02-26230B60C0E4Q36245823-90AEDBAC-6423-48A2-9E83-FD7B1965A88EQ36257726-0EC9AF5F-1E82-4B98-9091-920708A5EC81Q36368634-00EC16A2-7EE5-4CB0-89E0-6CAAF638A245Q36828146-3D74A3DB-6C37-46D2-8B85-240E51C8A5CDQ36842799-AC74AB88-8259-4140-BD6D-EE03F8DCD907Q37627736-FC69742F-D772-42DF-9830-02A7D347236CQ38415330-0D6CB8F5-8BCE-4F56-BE5D-C935E14D56E7Q38463463-5029962D-9760-46B2-9D35-A124DFE76739Q39039446-1E79E42C-BD1D-4B33-BAC8-644AA9BA4C73Q39310832-A7E29FCD-F90D-42AD-8023-83E17405D3F7Q39414535-C799E747-2FB1-4BFA-8BDD-5F182377B987Q39427264-7887ACC5-26A0-4913-ADD1-07C4E762179EQ42292862-D7E94EF1-859D-450E-A304-0E27ECC55C51Q42744024-7611CCBA-94AE-46AF-BFA6-629D3C89EEE1Q47149927-01A1801A-5A00-4E0E-9D91-9F9220453A09Q47559649-F36EA4CE-8AD8-4F58-B39C-0212EA76320BQ47758215-74746A49-BFC6-43CE-A373-19B45B594B09Q49205192-741FB090-0B21-4771-AAFC-69CB52F07812
P2860
Anti-vascular endothelial growth factor for diabetic macular oedema
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-vascular endothelial growth factor for diabetic macular oedema
@ast
Anti-vascular endothelial growth factor for diabetic macular oedema
@en
Anti-vascular endothelial growth factor for diabetic macular oedema
@nl
type
label
Anti-vascular endothelial growth factor for diabetic macular oedema
@ast
Anti-vascular endothelial growth factor for diabetic macular oedema
@en
Anti-vascular endothelial growth factor for diabetic macular oedema
@nl
prefLabel
Anti-vascular endothelial growth factor for diabetic macular oedema
@ast
Anti-vascular endothelial growth factor for diabetic macular oedema
@en
Anti-vascular endothelial growth factor for diabetic macular oedema
@nl
P2860
P3181
P1476
Anti-vascular endothelial growth factor for diabetic macular oedema
@en
P2093
Francesca Menchini
Mariacristina Parravano
P2860
P3181
P356
10.1002/14651858.CD007419.PUB4
P577
2014-10-24T00:00:00Z